Unveiling a series of policies meant to mitigate the threat of COVID-19, President Donald Trump also sought to respond to criticism that his administration has been slow to deal with what is now a worldwide pandemic.
During the 2020 State of the Union address, President Donald Trump zeroed in on prescription drug prices, arguing that his administration is “taking on the big pharmaceutical companies.”
At the January Democratic debate, Vermont Sen. Bernie Sanders zeroed in on the question of profits in the health care industry.
Under “Medicare for All,” he said, “we end the $100 billion a year that the health care industry makes.”
With the 2020 election months away, President Donald Trump’s reelection campaign is touting his health care record as a key reason voters should grant him another term.
Articulating his proposal for health care reform, former Vice President Joe Biden emphasized the number of Americans who, he said, were more than perfectly satisfied with the coverage they have.
Speaking about a recent federal advisory on marijuana, Dr.
Delivering remarks on surprise medical billing, which is a concern that has drawn bipartisan interest, President Donald Trump waded into another high-profile health issue: making
Private health insurance plans in 2017 paid more than twice what Medicare would have for those same health care services, says a sweeping new study from Rand Corp., a respected research organization.
At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions.
When the American Medical Association — one of the nation’s most powerful health care groups — met in Chicago this June, its medical student caucus seized an opportunity for change.
